Colistin Crosslinked Gemcitabine Micelles to Eliminate Tumor Drug Resistance Caused by Intratumoral Microorganisms

Bioconjug Chem. 2022 Oct 19;33(10):1944-1952. doi: 10.1021/acs.bioconjchem.2c00407. Epub 2022 Oct 3.

Abstract

In the tumor microenvironment, there exist microorganisms that metabolize anticancer drugs, leading to chemotherapy failure. To solve this problem, herein, we develop antibiotic and anticancer drug co-delivery micelles, termed colistin crosslinked gemcitabine micelle (CCGM). A self-immolative linker enables colistin and gemcitabine to be released on demand without affecting their antibacterial and anticancer effects. Once CCGM is delivered to the tumor microenvironment, intracellular glutathione triggers the release of colistin and gemcitabine, inhibiting the growth of microbes in the tumor, thus eliminating the microbe-induced drug resistance of tumor.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Bacterial Agents / pharmacology
  • Anti-Bacterial Agents / therapeutic use
  • Antineoplastic Agents* / pharmacology
  • Antineoplastic Agents* / therapeutic use
  • Cell Line, Tumor
  • Colistin / pharmacology
  • Drug Resistance, Neoplasm
  • Gemcitabine
  • Glutathione
  • Micelles*

Substances

  • Micelles
  • Colistin
  • Antineoplastic Agents
  • Glutathione
  • Anti-Bacterial Agents
  • Gemcitabine